SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy
Anh N. Le,
Madeline L. Good,
Seth D. Jeffries,
Yolanda R. Kry,
Emily M. Kugler,
Stacy L. Pundock,
Lisa A. Varughese,
Shefali Setia Verma,
Madison E. Weirick,
Christopher M. McAllister,
Daniel J. Rader,
Robert H Vonderheide,
Lynn M Schuchter,
Scott E. Hensley,
E. Paul Wileyto,
Alexander C Huang,
Kara N Maxwell,
Posted 16 Jan 2021
medRxiv DOI: 10.1101/2021.01.15.21249810
Posted 16 Jan 2021
Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. To gauge the effectiveness of these measures at the University of Pennsylvania, we conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between 5/21/2020 and 10/8/2020. Participants completed questionnaires and had up to five serial blood collections. Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95%CI 0.0-4.1%) over 14.8 person-years of follow up, with a median of 13 healthcare visits per patient. These results suggest that cancer patients receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.
- Downloaded 1,654 times
- Download rankings, all-time:
- Site-wide: 11,287
- In oncology: 13
- Year to date:
- Site-wide: 1,377
- Since beginning of last month:
- Site-wide: 10,439
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!